We compared the sensitivity of the polymerase chain-reaction (PCR) assay to that of slot-blot hybridization for detecting hepatitis B virus (HBV) DNA in the serum of 31 patients with chronic hepatitis. Of 14 chronic hepatitis patients positive for both HBV surface and HBV e antigens, 9 were positive for HBV DNA by slot-blot hybridization and all 14 by PCR. Also, of 9 patients positive for HBV surface antigen and antibody against HBV e antigen, 2 were positive for HBV DNA by slot-blot analysis and 8 by PCR. Finally, in 8 patients positive for antibody against HBV surface antigen, none were positive for HBV DNA by slot-blot hybridization, but 4 were positive by PCR. We find that analysis by the PCR technique provides a >104-fold increase in sensitivity over the slot-blot hybridization assay. This result represents an important breakthrough in sensitivity because it is now possible to detect as few as three HBV DNA genomes per sample of serum.
The polymerase chain reaction (PCR) technique is a method for amplifying nucleic acid by repeated cycles of hightemperature template denaturation, oligonucleotide primer hybridization, and polymerase extension. The thermostable polymerase of Thermus aquaticus (Taq) is often used because it can withstand the high denaturation temperatures without loss of enzymatic activity. Previous investigations with this technique have shown amplification of >105-fold over the input quantity of nucleic acid (1, 2) . We have used PCR amplification, combined with agarose gel electrophoresis and Southern blot hybridization analysis, to detect extremely small quantities of hepatitis B virus (HBV) DNA in the serum of chronic hepatitis patients.
MATERIALS AND METHODS
Patient Population. A group of 31 patients with chronic hepatitis were admitted to Kanazawa University Hospital (Kanazawa, Japan). Group A consisted of 14 patients with chronic hepatitis whose sera contained HBV surface antigen (HBsAg), antibody to HBV core antigen (anti-HBc), and HBV e antigen (HBeAg) for at least 1 yr. Group B consisted of 9 patients with chronic hepatitis whose sera tested positive for HBsAg, anti-HBc, and antibody against HBeAg (antiHBe) for at least 6 months. Group C consisted of 8 patients with chronic hepatitis whose sera were positive for antibody against HBsAg (anti-HBs) ( Table 1) .
Serological Methods. Serological assays for HBV markers (HBsAg, anti-HBs, anti-HBc, HBeAg, and anti-HBe) were performed by RIA using commercially available reagent kits (Ausria II for HBsAg, Ausab for anti-HBs, and Corab for anti-HBc and HBeAg/anti-HBe, Abbott). The anti-HBc titer was considered negative when the percent inhibition in the Corab assay was <30%.
Preparation of DNA Samples. One hundred microliters of serum was incubated at 70TC for 3 hr in proteinase K (100 ,ug/ml)/0.5% NaDodSO4/5 mM EDTA/10 mM Tris HCI, pH 8 (4, 5) . Hybridization, with recombinant HBV DNA labeled to high specific activity (2-4 x 108 cpm/pAg), was performed in the above buffer at 420C for 24 hr. After hybridization, membranes were washed twice in 1x SSC and 0.1% NaDodSO4 for 5 min at room temperature and three times in 0.1x SSC/0.1% NaDodSO4 at 650C for 30 min per wash. Membranes were exposed to x-ray film (XAR, Kodak) for autoradiography. For slot-blot hybridization, 2.5 A.l of serum DNA was denatured with 0.1 M NaOH in a final volume of 20,Al for5 min, mixed with 180 Al of 1.0 M ammonium acetate, and the DNA was fixed to a nylon membrane. Hybridization analysis was as described above.
RESULTS AND DISCUSSION
Establishing the Sensitivity of the PCR Technique by Amplification of Recombinant HBV DNA. The presence of serum HBV DNA in chronic hepatitis patients indicates active virus replication. The most sensitive method for detecting serum HBV DNA currently in use is molecular hybridization analysis. Slot-, or dot-, blot hybridization analysis can detect <0.1 pg of HBV DNA (6) (7) (8) . However, PCR amplification of virus DNA is a more sensitive assay, potentially, than molecular hybridization. The PCR assay amplifies nucleic acid sequences >105-fold with the use of specific oligonucleotide primers. Therefore, PCR amplification, coupled with molecular hybridization analysis, is theoretically capable of detecting attogram (10-18 g) levels of HBV DNA in the original sample.
To determine the lower limit of detection of HBV DNA in our experiments, 10-fold serial dilutions of cloned HBV DNA were analyzed by PCR with oligonucleotide primers specific for the core gene sequence of HBV. After PCR amplification, DNA was fractionated by agarose-gel electrophoresis and visualized under UV light by ethidium bromide fluorescence (the PCR-EB technique). Samples containing an initial quantity of .10-2 pg of recombinant HBV DNA produced a visible DNA band of expected size [i.e., 270 base pair (bp)] by ethidium bromide fluorescence (Fig. 1A, lanes 2-4) . Thus, the sensitivity of the PCR-EB assay was 10-fold greater than the slot-blot hybridization assay for detecting HBV DNA. In addition, because PCR-EB analysis is faster and potentially more convenient than molecular hybridization, it may become useful for routine clinical diagnosis of virus DNA.
The sensitivity of PCR-SBH was found to be -1000-fold greater than that of PCR-EB for detecting HBV DNA. After gel electrophoresis and ethidium bromide staining, PCRamplified HBV DNA was transferred to a nylon membrane and hybridized to a 32P-labeled HBV DNA probe (Fig. 1B) . PCR-SBH analysis could detect as little as 10-5 pg (10 ag) of HBV DNA in the original sample (Fig. 1B, lane 7) . Overall, we find that the recombinant HBV DNA in the samples was amplified >105-fold, which is in good agreement with the levels of amplification achieved by others (1, 2) and that PCR-SBH was 104-fold more sensitive than slot-blot hybridization for detecting HBV DNA.
Detection of HBV DNA in the Serum of Patients with Chronic Hepatitis Positive for HBsAg, Anti-HBc, and HBeAg.
The presence of HBsAg in serum, detected by RIA, is used to identify the chronic carrier state of HBV infection. In the past, endogenous DNA polymerase activity in serum was indicative of active virus replication in the host. Recently, slot-blot hybridization analysis, because of its greater sensitivity, has replaced the endogenous DNA polymerase reac- tion as the assay of choice for detecting serum HBV DNA. Analysis of sera by slot-blot hybridization has demonstrated that most, but not all, sera positive for HBeAg and HBsAg contain HBV DNA (6) (7) (8) (9) (10) (11) (12) (13) (14) (15) . In our study, the sera of 14 chronic hepatitis patients positive for HBeAg and HBsAg were assayed for the presence of HBV DNA by slot-blot hybridization and by PCR-EB and PCR-SBH analysis (Table  1) . Although only 9/14 (64%) sera tested positive for virus DNA by slot-blot hybridization, 13/14 (93%), and 14/14 (100%) sera tested positive for HBV DNA by PCR-EB and PCR-SBH, respectively (Fig. 2) . Therefore, PCR-SBH analysis was able to detect HBV DNA in all sera that were positive for HBeAg and HBsAg. On the other hand, HBV DNA is often detected in the liver of patients with chronic hepatitis (8, (10) (11) (12) (13) (14) . In one study, 0/9 chronic carriers were positive for serum HBV DNA, and 4/9
were positive for HBV DNA in the liver (9) . Thus, it is likely that circulating virions were present in at least 4/9 patients but were below the detection limit of current technology. Therefore the presence of anti-HBe in the serum of chronic hepatitis patients is not an accurate marker for cessation of virus replication in the host.
In our study, the sera of 9 chronic hepatitis patients positive for HBsAg, anti-HBc, and anti-HBe were analyzed for the presence of HJ3V DNA by the slot-blot hybridization and PCR techniques. Although only 2/9 (22%) patients tested positive for serum HBV DNA by slot-blot hybridization analysis, 3/9 (33%) and 8/9 (89%) tested positive by PCR-EB and PCR-SBH, respectively (Table 1) . Thus, nearly all of the patients positive for HBsAg, anti-HBc, and anti-HBe in our study possessed circulating virus particles because we detected the presence of serum HBV DNA. This result suggests that seroconversion from HBeAg to anti-HBe can be accompanied by a decrease, but not a total disappearance, of virus particles in the serum.
With PCR-SBH nearly all (i.e., 22/23) of the HBsAgpositive chronic hepatitis patients in our study group possessed serum HBV DNA, irrespective of their HBeAg/antiHBe status. This finding supports the hypothesis that HBV continues to replicate in the liver of HBsAg-positive patients after seroconversion to anti-HBe, and that complete virions, in addition to HBsAg particles, continue to be released into the serum. However, we found that 1/9 patients positive for HBsAg and anti-HBe lacked detectable serum HBV DNA. There are at least two explanations for this result: (i) Virus replication is occurring in tissue but the titer of virus in the serum is low, and the amount of HBV DNA present is below our detection limits. (ii) Virus replication may not be occurring with HBsAg expressed from HBV genomes that are integrated into the host genome, analogous to HBV DNAcontaining hepatoma cell lines (16 (Table 2 ). The amplified HBV DNA sequences from patient sera were sig- nificantly different from the recombinant HBV DNA used in our laboratory. The differences ranged from 2-15% over a nucleotide length of 198 bp. However, the DNA from one patient, patient 26, possessed a nucleotide sequence that was identical to the recombinant HBV DNA used in our laboratory and, therefore, may represent exogenous recombinant HBV DNA that was amplified in the serum sample. Overall, the sequences of HBV DNA amplified from the sera of chronic hepatitis patients were specific, which suggests that they did not arise from contaminating recombinant HBV DNA.
In summary, we find that 26/31 (84%) of the chronic hepatitis patients in our study possess serum HBV DNA that is detected by PCR analysis. This suggests that such patients continue to support active HBV replication. In addition, it is clear that serological analysis is not sufficient for predicting the course of chronic liver disease. PCR analysis offers several advantages over other methods for detecting serum HBV DNA. PCR-EB analysis is 10-fold more sensitive, can be performed faster, and, under stringent conditions, can be more specific than slot-blot hybridization analysis. Further, PCR-SBH offers even more advantages over slot-blot hybridization-it is 104-fold more sensitive and is a more specific assay (i.e., because it uses hybridization of an amplified DNA fragment of specific size with a virus-specific radiolabeled probe). However, care must be exercised to eliminate sources of contaminating HBV DNA from samples and reagents. It is clear that the PCR technique represents a significant advance in analyzing serum samples because it is possible to detect HBV DNA isolated from samples containing only three virions. This technique should revolutionize diagnostic assays for detecting virus DNA and yield valuable information on the biology of HBV.
